Management of Colorectal Cancer Distant Metastases

Surgical, ablative, and sequencing framework for stage IV (metastatic) colorectal cancer — the wiki's first dedicated treatment of this topic. Content below is from a textbook reference chapter (ASCRS Ch31 - Colorectal Cancer Management of Distant Metastases), not primary literature. This page covers the procedural/sequencing side of metastatic CRC management (primary-tumor management, resectability determination, liver/lung resection technique, locoregional ablative/embolic therapies, uncommon metastatic sites). See Rectal Cancer's Survival, surveillance, and adjuvant chemotherapy section (Metastatic disease subsection) for this wiki's existing systemic chemotherapy regimen framework (FOLFOX/FOLFIRI/FOLFOXIRI ± bevacizumab, anti-EGFR agent selection by RAS/BRAF status and tumor sidedness) — that content remains authoritative and is cross-linked, not duplicated, below.

Epidemiology and framing

Up to 22% of colorectal cancer patients present with metastatic disease at initial diagnosis. Overall 5-year survival in stage IV CRC is 10–14%, but this is highly dependent on extent/site of metastases — 5-year survival ranges from 24% to 58% (averaging 40%) in patients with resectable hepatic metastases. The liver is the dominant metastatic site, accounting for 75% of CRC metastases, followed by the lung (22%); over 70% of patients with lung metastases also have synchronous liver metastases. The brain, bone, ovary, peritoneum, and adrenals make up the remaining less common metastatic sites (see Other sites of metastases, below). Prognosis relates to volume and site of metastases, with oligometastases carrying a better prognosis than multi-organ metastatic disease — a SEER-database analysis found 3-year overall survival of 26.8% and 34.0% for patients with a solitary metastasis to the liver and lung, respectively.

Multidisciplinary evaluation: treatment of metastatic CRC has evolved toward more aggressive therapy in recognition of the potential for long-term survival. Neither NCCN nor ASCRS guidelines recommend one treatment strategy over another, particularly for resectable metastatic disease — care requires a comprehensive multidisciplinary approach to develop an individualized treatment scheme integrating quality of life and patient goals, with shared decision-making between patient and team.

Synchronous metastases

The patient presenting with metastatic disease at initial diagnosis requires an individualized approach based on functional status, treatment goals, site/volume of metastatic disease, and degree of primary-tumor-related symptoms. Fig. 31.1 (treatment algorithm for synchronous CRC liver and/or lung metastases): a multidisciplinary discussion first determines resectability of both primary and metastases → if the primary is resectable, "stent, divert, or resect" if symptomatic, otherwise proceed to resection of primary with chemotherapy and resection of metastases in some sequence → if unresectable at any point, chemotherapy with reimaging every 8 weeks to reassess for conversion to resectability.

Management of the primary tumor

• Bleeding: most patients with symptomatic anemia from primary-tumor blood loss can be managed non-operatively, since ongoing loss is typically low-volume. Rarely, significant blood loss requires surgery, particularly with mandatory chronic anticoagulation or tumor involvement of a mesenteric/ surrounding vascular structure. Management depends on tumor location/size and bleeding rate: radiation provides relatively quick, effective palliation for surface bleeding (particularly rectal); resection is preferred when feasible, especially for more proximal cancers or significant hemorrhage, but depends on local invasion into adjacent structures, functional status, and metastatic burden. Endovascular procedures (embolization, covered stent placement) are also available palliatively.
• Obstruction: 8–30% of CRC patients present with a partial or complete obstructing primary lesion. Complete obstruction is straightforward to recognize; impending obstruction is more nuanced (constipation, diarrhea, tenesmus, weight loss, postprandial colicky pain, distention; failure to pass the endoscope past the lesion; a stool column proximal to the lesion with absent distal stool on cross-sectional imaging even without frank dilation). Interventional options depend on tumor size/ location: ASCRS guidelines recommend considering decompressive stent insertion prior to colectomy or diversion for an obstructing colon cancer with incurable metastatic disease — colonic stenting reduces short-term morbidity and time-to-chemotherapy-initiation vs. surgery with no OS impact, but stenting success is anatomically variable (acute colonic angulation; distal rectal tumors are often not amenable given the distal stent end sitting on the anorectal muscular ring) and stents can ultimately erode through the bowel wall (abscess/fistula) — median stent patency is 106 (68–288) days. Resection may be preferable for an easily resectable primary in a patient expected to live ≥6 months, with a low threshold for fecal diversion given staged-reconstruction possibility. Proximal diversion is valuable for locally invasive/rectal lesions difficult to resect — the distal bowel should always be vented (loop or divided end-loop stoma) to avoid closed-loop obstruction/perforation; anticipate the ultimate definitive resection when choosing a diversion site (misplaced stomas can compromise future reconstructive options or devascularize the distal colon after high IMA ligation during a subsequent LAR — prefer the mid-/proximal sigmoid or proximal transverse colon just right of the middle colic artery for diverting obstructing rectal tumors). A loop ileostomy has the least influence on the "next" operation but risks closed-loop physiology if the ileocecal valve is competent and the distal tumor completely obstructing, plus dehydration/chemotherapy-enteritis risk.
• Perforation: exploration warrants resection vs. diversion based on feasibility of resection, following oncologic principles if possible — but aggressive en bloc resection of vital structures is rarely indicated given the overall poor prognosis of a perforated tumor with metastatic disease; priority is source control of intra-abdominal infection (simple diversion if contained, or percutaneous/surgical drainage).

Unresectable synchronous metastases

Survival is closely linked to control of the distant disease, so control of metastatic disease should be prioritized — early determination of whether the patient has potentially curable metastases is necessary to set the treatment strategy. NCCN and ASCRS guidelines recommend systemic chemotherapy for patients with minimally symptomatic primaries; surgery is reserved for imminent risk of obstruction, significant bleeding, perforation, or other significant tumor-related symptoms — few patients (<20%) with metastatic CRC require palliative primary-tumor intervention during chemotherapy. There has been a philosophical shift away from prophylactic resection of the asymptomatic primary in unresectable metastatic disease (84% resected in 2000 vs. 52% in 2011) toward upfront systemic chemotherapy, though it remains unclear whether resecting the primary ultimately improves survival in this setting — retrospective data suggest a survival benefit from chemotherapy + primary resection vs. chemotherapy alone (DFS/OS improvements of 6–14 months reported), but all such studies are retrospective and subject to selection bias. Several ongoing prospective trials (JCOG1007, CAIRO4, GRECCAR 8) may clarify resection's efficacy; for now, the decision should be individualized based on response to chemotherapy, estimated prognosis, and patient preference.

Chemotherapy options in unresectable synchronous metastatic disease: FOLFOX, FOLFIRI, CAPEOX, or FOLFOXIRI ± bevacizumab (see Rectal Cancer's Metastatic disease section for the fuller regimen- selection framework by RAS/BRAF status and tumor sidedness — this chapter's regimen list corroborates rather than extends that content). NCCN recommends reevaluation with cross-sectional imaging every 2 months to monitor for conversion to resectability; if bevacizumab was used and surgery becomes planned, a 6-week interval between last bevacizumab dose and elective surgery is recommended, with re-initiation at least 6–8 weeks postoperatively.

Resection-first vs. chemotherapy-first sequencing — advantages/disadvantages must be weighed by multidisciplinary tumor board:

• Resection-first advantages: eliminates tumor-cell shedding from the primary during systemic treatment; avoids emergent surgery if the primary progresses while on chemotherapy.
• Neoadjuvant-chemotherapy-first advantages: eliminates micrometastatic disease; cytoreduction may facilitate R0 resection or convert unresectable to resectable disease; avoids potential surgical complications that could delay chemotherapy initiation; initial chemotherapy response may reveal aggressive tumor biology, avoiding futile surgery in patients who progress on systemic treatment regardless.
• Caveat: increased perioperative morbidity and liver toxicity (steatohepatitis, sinusoidal obstruction syndrome, noncirrhotic portal hypertension) has been reported following neoadjuvant chemotherapy — regardless of regimen chosen, NCCN recommends limiting neoadjuvant chemotherapy duration to 2–3 months in patients with clearly resectable disease, with the remaining ~3 months of perioperative chemotherapy given after surgery.

Resectable synchronous metastases

Approximately 20% of patients with CRC metastases have resectable or potentially resectable disease. Multiple sequencing options exist (Fig. 31.3, illustrated via NCCN-guideline-framework clinical vignettes):

1. Synchronous or staged colectomy with liver/lung resection (preferred) and/or local ablative procedures, followed by 6 months adjuvant chemotherapy — best suited to small, solitary, peripheral metastases at lowest surgical morbidity/mortality risk (e.g. an otherwise-healthy patient with a colon primary and a solitary 2cm peripheral liver metastasis).
2. Neoadjuvant chemotherapy (2–3 months) followed by synchronous or staged colectomy and metastasis resection, followed by the remaining 3–4 months of adjuvant therapy — appropriate for patients with multiple (>4) liver metastases and an asymptomatic primary (increasing metastatic burden raises post-hepatectomy recurrence risk, favoring an initial systemic-response assessment).
3. Colectomy followed by chemotherapy (2–3 months) and staged resection of metastatic disease, followed by the remaining 3–4 months of adjuvant chemotherapy — appropriate when the primary poses an impending-obstruction risk and the hepatic metastasis is borderline resectable (e.g. a single 8cm hepatic metastasis) — upfront colon resection plus a chemotherapy-response interval before committing to complex hepatectomy.

Rectal cancer — added sequencing complexity

Locally advanced rectal cancer with synchronous resectable metastases adds pelvic radiotherapy to the sequencing question. Options include upfront chemotherapy followed by short-course radiotherapy or long-course chemoradiotherapy then resection (synchronous or staged), or upfront short-course radiotherapy followed by chemotherapy then resection. If radiotherapy is given first, short-course is attractive since it allows earlier initiation of multi-drug chemotherapy than long-course chemoradiotherapy; giving radiotherapy first also allows more accurate assessment of the primary tumor's response. A "wait-and-watch" (organ-preservation) approach for the primary might appeal to patients facing an APR with a complete clinical response — but prior watch-and-wait studies have excluded stage IV patients, so oncologic outcomes of watch-and-wait in the synchronous-resectable- metastatic setting have not been evaluated (see Watch and Wait (Nonoperative Management) for that page's stage II–III-only evidence base). There is some concern that delaying hepatic resection until completion of/recovery from systemic chemotherapy may worsen chemotherapy-induced liver changes and increase postoperative liver-failure risk if pelvic radiotherapy is planned after chemotherapy, followed by immediate surgery — one option to shorten time-to-resection in this scenario is short- course radiotherapy after chemotherapy, followed immediately by surgery. Alternatively, treating with 2–3 months neoadjuvant chemotherapy followed by liver resection, then the remaining ~3 months of perioperative chemotherapy plus chemoradiation/short-course radiation prior to resecting the rectal primary, is another option — with an added consideration of abdominal adhesions and radiation enteritis risk from sequencing radiation after a liver resection.

Metachronous metastases

Roughly 20% of CRC patients present with synchronous metastases at initial diagnosis; another 20% go on to develop metachronous metastases after initial curative treatment. Over 85% of metachronous metastases are diagnosed within 3 years of initial curative treatment. Site distribution differs somewhat from synchronous disease: liver remains most common (60%), followed by lungs (39%), extra-regional lymph nodes (22%), and peritoneum (19%).

Predictors of metachronous metastases (with hazard ratios): male gender (HR 1.2, 95% CI 1.03–1.32); advanced primary T-stage (T4 vs. T3 HR 1.6, 95% CI 1.32–1.90); N-stage (N1 vs. N0 HR 2.8, 95% CI 2.42–3.30; N2 vs. N0 HR 4.5, 95% CI 3.72–5.42); high-grade tumor differentiation (HR 1.4, 95% CI 1.17–1.62); positive resection margin (HR 2.1, 95% CI 1.68–2.71); and unknown resection margin (HR 1.7, 95% CI 1.34–2.22). Many of the same treatment principles described above for synchronous disease apply to metachronous disease, depending on resectability and whether adjuvant therapy was received within the prior 12 months (see Adjuvant Chemotherapy for Colorectal Cancer). In general, patients with metachronous disease have a better prognosis than patients with synchronous metastases.

Liver metastases

Resection

Surgical resection is associated with the highest cure rates of available treatment modalities for hepatic metastases — 5-year survival ranges 24–58% (averaging 40%), with 30-day mortality <3%. This compares to 5-year survival of only 10–11% for patients treated with systemic chemotherapy alone (heavily confounded by selection bias). Approximately 20% of patients with hepatic metastases are considered resectable at initial presentation; another 10% may become resectable after induction chemotherapy.

The definition of "resectable disease" has broadened significantly over time via a more aggressive surgical approach. Initially, resection criteria were limited to small, easily resectable, low-volume (<4 lesions) disease without extrahepatic disease. Criteria have since expanded to include multiple/bilobar metastases of varying size in the presence of extrahepatic disease (particularly lung). Close-margin or difficult-to-reach lesions can be managed with ablation (cryosurgery or radiofrequency ablation) or en bloc vascular resection with reconstruction to achieve R0. 3D imaging, portal vein embolization, and ALPPS have further expanded resection possibilities through more precise assessment and optimization of the future liver remnant (FLR). In the modern era, patients are considered resectable if fit enough to tolerate surgery and an R0 resection can be achieved while preserving enough viable hepatic parenchyma to sustain life.

• Future liver remnant (FLR) and portal vein embolization (PVE): FLR volume and the degree of hypertrophy achieved after PVE are important predictors of surgical outcome in patients undergoing major liver resection — 3D CT reconstruction is one of the most common measurement techniques. FLR

  30% of total hepatic volume is generally the minimum for patients who received chemotherapy for 12 weeks. Embolization/ligation of the portal vein can expand functional liver volume by 39% over 4–8 weeks (occasionally longer); risks include disease progression during the waiting interval and insufficient hypertrophy — a substantial fraction (25–38%) of patients progress and fail to undergo the planned staged hepatectomy.

• Staged hepatectomy for extensive bilobar disease: partial hepatectomies clear the FLR of disease first (in conjunction with portal vein ligation, potentially combined with primary-tumor resection in synchronous disease), then formal anatomic resection of the remaining diseased lobe follows in a second-stage operation once the FLR has hypertrophied without metastatic progression. Alternatively, PVE can be performed upfront with a single-stage hepatectomy once hypertrophy is adequate.
• ALPPS (associating liver partition and portal venous ligation for staged hepatectomy): an emerging technique in which the liver is surgically partitioned at the site of future transection (rather than only occluding the portal vein), theoretically producing much more rapid liver regrowth than portal vein occlusion alone — staged hepatectomy can proceed as soon as 7–10 days later. Initial series suggested increased liver growth rate/volume enabling faster resectability, but with significant morbidity/mortality that has limited widespread adoption. The LIGRO trial (Scandinavian multicenter RCT, 100 patients with advanced CRC liver metastases, ALPPS vs. conventional two-stage hepatectomy with portal vein ligation/embolization) found ALPPS associated with both a higher resection rate (92% vs. 80%, p=0.091) and better estimated median survival (46 vs. 26 months, p=0.028), with no differences in complication rates or 90-day mortality — but ALPPS has been called "the hepatobiliary controversy of the decade," reflecting a polarized view among leaders in the field; further study is needed, and portal vein embolization remains the standard of care for resectable liver metastases with FLR <30%.
• Laparoscopic vs. open resection: the majority of liver resections are performed open, but the randomized OSLO-COMET trial demonstrated shorter hospital stay (2 vs. 4 days, p<0.001), lower complication rates (19% vs. 31%, p=0.021), and better quality of life with laparoscopic vs. open resection for CRC liver metastases — with similar long-term oncologic outcomes (median OS 80 months, 95% CI 52–108, laparoscopic vs. 81 months, 95% CI 42–120, open; p=0.91). A laparoscopic approach should therefore be considered when anatomically feasible.

Locoregional therapies

Per NCCN guidelines, resection is preferred over locoregional therapies given better DFS/OS. However, approximately 80% of patients will have unresectable disease and may benefit from alternative locoregional therapies: percutaneous ablative treatments (radiofrequency ablation, microwave ablation) and transcatheter intra-arterial therapies (transarterial chemoembolization/TACE, radioembolization with yttrium-90). Many of these image-guided therapies can also be combined with resection to improve resectability.

Table 31.1 — treatment options in patients with hepatic CRC metastases (Modality | Mechanism | Indication | Survival | Risks):

• Radiofrequency ablation (RFA): thermal damage via high-frequency alternating current (375–500 kHz) causing cytotoxicity within a few millimeters of the surrounding thermal zone; water evaporation causes desiccation and electrical impedance limiting thermal transmission volume — RFA is therefore limited to a relatively small treatment zone, and flowing blood in large adjacent vessels causes a cooling ("heat sink") effect that reduces ablation volume/efficacy near large vessels. Well tolerated overall (major complication rate 6–9%, mortality <2%); most effective for peripheral lesions <3cm; may be performed open, laparoscopic, or percutaneous, and can be combined with surgical resection. Median OS following RFA ranges 28–53 months — superior to chemotherapy alone but inferior to surgical resection.
• Microwave ablation (MWA): electromagnetic signal generates heat via molecular friction (900–2450 MHz), causing coagulation necrosis. Has gained favor over RFA for faster heating over larger tissue volumes and resistance to the heat-sink effect — can treat tumors >3cm and those near hepatic vessels with similar/improved recurrence rates vs. RFA. A recent meta-analysis found median 5-year OS 43% for RFA vs. 55% for MWA, compared to 20% for chemotherapy alone.
• Transcatheter intra-arterial techniques: reserved for unresectable oligometastatic disease in patients who aren't ablation candidates and have failed systemic chemotherapy. TACE delivers chemotherapeutic agents (mitomycin, doxorubicin, cisplatin) emulsified with lipiodol, plus an embolic agent (traditionally polyvinyl alcohol or gelfoam), into the hepatic arteries supplying the tumor — pioneered in hepatocellular carcinoma, considered a salvage option for liver-limited metastatic CRC patients failing systemic chemotherapy; OS rates are low (median 8–9 months). Side effects (fever, RUQ pain, nausea, vomiting) are collectively termed "post-embolization syndrome" (occurring in 60–80%). Drug-eluting beads (DEBs) have recently replaced polyvinyl alcohol/ gelfoam as embolic agents, allowing slower/more sustained chemotherapeutic release directly into liver tumors, theoretically reducing systemic drug exposure/side effects — irinotecan-loaded DEBs (DEBIRI) are the most widely studied, with average toxicity 10% and OS 16 months. Martin et al. randomized 70 chemo-naïve patients with unresectable CRC hepatic metastases to FOLFOX+bevacizumab vs. FOLFOX+bevacizumab+DEBIRI (FOLFOX-DEBIRI): higher response rates and significantly improved downsizing-to-resection at 6 months with FOLFOX-DEBIRI (35% vs. 6%, p=0.05), but no difference in progression-free survival and no OS data presented — further study needed to define DEB-TACE's role.
• Transarterial radioembolization (TARE), also known as selective internal radiotherapy (SIRT): microspheres loaded with a radioisotope (yttrium-90, a ß-emitter) deliver high-dose radiation to liver tumors via an intra-arterial catheter-based technique — one of the initial transcatheter techniques used as salvage for patients failing systemic chemotherapy; response rates 35–40% with median survival 8–14 months. A pooled analysis of three RCTs (FOXFIRE, SIRFLOX, FOXFIRE-Global, 1103 patients with liver-only and liver-dominant metastatic CRC) demonstrated higher toxicity and no difference in OS with SIRT/⁹⁰Y added to FOLFOX vs. FOLFOX alone — the exact role of this technique in the metastatic-CRC armamentarium remains to be seen.
• Stereotactic body radiation therapy (SBRT): extremely precise external beam radiation using sophisticated 4D CT imaging to deliver intense radiation doses (e.g. 25Gy in three consecutive daily fractions for a total dose of 75Gy to target, with a thermoplastic mask and Styrofoam abdominal compression for immobilization). 5-year follow-up from a phase II trial on SBRT for unresectable liver metastases demonstrated median OS 27.6 months with 5-year survival 18%; two large international registries (>400 patients with hepatic metastases) showed median OS 24–27 months post-SBRT — comparable to median OS 23.3 months with oxaliplatin-based chemotherapy alone in unresectable hepatic CRC metastases, so it remains unclear whether SBRT improves survival over modern chemotherapy alone.

Lung metastases

The lung is the second most common site of CRC metastatic disease (22%). Isolated lung metastases are generally associated with a better prognosis than isolated liver metastases (5-year OS up to 68%). Many of the same treatment modalities used for hepatic metastases are available for pulmonary metastases: resection, ablative techniques, radiotherapy, and chemotherapy — multidisciplinary input is similarly essential.

Surgical resection of pulmonary metastases (pulmonary metastasectomy, PM) is common practice, but surprisingly there has not been a single prospective trial evaluating its effectiveness — practice patterns are instead defined through retrospective series and international registries, limited by selection bias, inconsistent systemic treatment, variable follow-up length, and lack of comparative survival analyses. An ongoing trial (PulMiCC) randomizes metastatic-CRC patients to resection vs. surveillance. The Society of Thoracic Surgeons (STS) published an Expert Consensus Task Force document using the modified Delphi method; NCCN guidelines also provide pulmonary-resection-specific recommendations. The goal of PM is complete resection based on tumor location/extent while preserving adequate functional lung — lobectomy is generally discouraged in favor of formal wedge resection (sublobar) when possible given the metastatic-disease context; pneumonectomy is generally discouraged. There is no defined contraindication to PM based on the number of pulmonary metastases as long as an R0 resection can be achieved, and re-resection is appropriate in select patients with manageable extrapulmonary disease. Minimally invasive (thoracoscopic) techniques are preferred over open PM, though localization of small lesions can be challenging (finger/instrument palpation through port sites, percutaneous coils, wire localization, agar injection, dyes — no technique has demonstrated clear superiority). Mediastinal lymph node metastases occur in up to 44% of pulmonary-metastasis patients and are associated with worse survival; some advocate routine LN sampling/dissection at the time of PM for prognostic information and to guide subsequent systemic therapy, though STS guidelines found no uniform recommendation on this point. PM is associated with low morbidity (11%) and mortality (1.1%), with average LOS 4–7 days in properly selected patients.

STS guidelines suggest ablative techniques and SBRT are both reasonable therapy for oligometastatic pulmonary disease, particularly for high-risk patients or those who refuse resection — NCCN guidelines are less definitive on recommending resection over locoregional modalities for pulmonary metastases specifically, suggesting ablative techniques may be considered alone or combined with resection for resectable pulmonary metastases.

Other sites of metastases

Ovarian metastases

Approximately 5–10% of women with CRC develop ovarian metastases, with a preponderance toward younger patients; median survival 19–27 months. Ovarian metastases can reach significant size before becoming symptomatic and are disproportionately unresponsive to chemotherapy compared to other metastatic sites. The term Krukenberg tumor has been loosely (and incorrectly) applied to all metastatic ovarian tumors — true Krukenberg tumors are secondary carcinomas containing >10% mucin-filled signet-ring cells and are most commonly gastric in origin. Hematogenous spread accounts for the most common route of CRC ovarian metastasis (evidenced by the association with vascular invasion and low rate of lympho-angio invasion); transcoelomic dissemination doesn't appear to play a major role in most cases (evidenced by the smooth capsular surface of affected ovaries absent surface tumor deposits). Immunohistochemistry helps distinguish ovarian CRC metastases from primary ovarian malignancy (mucinous adenocarcinomas): ovarian primaries typically CK7+/CA125+/CK20−/CEA−/CDX2−, vs. the converse immunophenotype (CK20+/CEA+/CDX2+/CK7−/CA125−) in metastatic CRC. Synchronous ovarian metastases are more common than metachronous. Indications for oophorectomy in the synchronous setting include grossly abnormal ovaries or contiguous extension of the colorectal cancer into the ovarian capsule — prophylactic oophorectomy of normal-appearing ovaries, traditionally advocated to remove potential microscopic "undetectable" synchronous disease, is no longer generally recommended; NCCN guidelines specifically state "routine prophylactic oophorectomy is not necessary." Reoperation for oophorectomy may be reasonable in the metachronous setting given that ovarian metastases are less chemo-responsive than other sites and can grow large/symptomatic — depending on performance status and disease burden elsewhere. As with all metastatic sites, overall survival is improved with an R0/R1 resection.

Brain metastases

Approximately 1–4% of CRC patients develop brain metastases, generally in the context of diffuse widespread metastatic disease — isolated brain metastases are rare, and brain imaging is not routinely performed during initial staging or metastatic workup absent neurologic signs/symptoms. Treatment options include surgery, whole-brain radiation therapy (WBRT), and stereotactic radiosurgery (SRS). Surgery is preferred for an isolated brain metastasis, though resection of a single brain metastasis carries a 50–60% risk of local recurrence within 1 year. SRS has replaced WBRT in the adjuvant setting given its improved side-effect profile and reduced local-recurrence risk; SRS is also indicated for small unresectable solitary tumors or a limited number of brain metastases <3cm. WBRT is reserved for patients with multiple intracranial metastases who aren't surgery/SRS candidates — associated with significant side effects (fatigue, alopecia, neurocognitive decline) and does not improve OS. Palliative options include steroids for peritumoral edema and anticonvulsants for seizure prophylaxis.

Adrenal metastases

Adrenal metastases are uncommon in metastatic CRC and usually develop late in the disease course. Surgery is rarely an option, though case reports describe prolonged survival following resection of isolated adrenal metastases.

Surveillance

There is a paucity of data guiding posttreatment surveillance in patients with metastatic CRC treated with curative intent. NCCN guidelines suggest utilizing the same strategy as stage II/III CRC (see Colorectal Cancer Surveillance After Curative Treatment) with more frequent cross-sectional imaging: history and physical every 3–6 months for 2 years then every 6 months to a total of 5 years; CEA every 3–6 months for 2 years then every 6 months to a total of 5 years; chest/abdominal/pelvic CT every 3–6 months for 2 years then every 6–12 months to a total of 5 years; colonoscopy 1 year after surgery.

Related pages

• Rectal Cancer — this wiki's existing systemic-chemotherapy regimen framework for metastatic disease (FOLFOX/FOLFIRI/FOLFOXIRI ± bevacizumab by RAS/BRAF status and tumor sidedness), which this page's Unresectable synchronous metastases section corroborates rather than duplicates. Cytoreductive Surgery and HIPEC — the distinct clinical scenario of colorectal peritoneal metastases, cross-linked from that same section.
• Adjuvant Chemotherapy for Colorectal Cancer and Colorectal Cancer Surveillance After Curative Treatment — the companion stage I–III postoperative topics from the immediately preceding textbook chapter; this page's Surveillance section explicitly borrows the stage II/III surveillance framework from the latter.
• Watch and Wait (Nonoperative Management) — the organ-preservation strategy referenced (and its stage-IV evidence gap flagged) in this page's Rectal cancer sequencing-complexity section.
• Total Mesorectal Excision (TME) & Sphincter-Sparing Resection and Abdominoperineal Resection (APR) — the primary-tumor resection procedures this page's synchronous-metastases sequencing discussion assumes.
• Colorectal Cancer Staging (TNM) — the M-category/stage IV formal staging framework underlying this page's topic.

Open items / gaps

• No primary literature yet on any of this chapter's named trials (OSLO-COMET, LIGRO, FOXFIRE/ SIRFLOX/FOXFIRE-Global, Martin et al.'s FOLFOX-DEBIRI RCT, the SEER solitary-metastasis analysis, the STS Expert Consensus Task Force document) — all textbook-secondary-source-level, per ASCRS Ch31 - Colorectal Cancer Management of Distant Metastases.
• The ongoing PulMiCC and JCOG1007/CAIRO4/GRECCAR 8 trials (pulmonary metastasectomy efficacy and primary-tumor-resection efficacy in unresectable synchronous metastatic disease, respectively) are referenced as pending — worth revisiting once results mature.
• No dedicated primary-literature-sourced page yet exists for hepatic-metastasis-specific surgical technique (this page's Liver metastases section is the wiki's first treatment of the topic, entirely textbook-sourced).